Acute, subchronic and chronic toxicity of the new sulfonylurea glimepiride in rats.
Glimepiride (Hoe 490, CAS 93479-97-1) a new sulfonylurea, was tested in acute, subchronic and chronic toxicity studies in rats. The acute toxicity after oral or intraperitoneal administration was very low, all animals survived the maximum administrable dose levels (10,000 mg/kg orally; 3950 mg/kg intraperitoneally). In subchronic and chronic toxicity studies glimepiride was devoid of any significant toxic effects or pathological changes even at high dose levels. Pharmacodynamic effects were present as expected, i.e. decrease in serum glucose levels and degranulation of beta-cells in pancreas.
Donaubauer
H H
HH
Pharma Development Toxicology, Hoechst Aktiengesellschaft, Frankfurt/Main, Fed. Rep. of Germany.
Mayer
D
D
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003594:Cytoplasmic Granules / Q000187:drug effects; D005260:Female; D007004:Hypoglycemic Agents / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D007515:Islets of Langerhans / Q000187:drug effects / Q000648:ultrastructure; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013453:Sulfonylurea Compounds / Q000633:toxicity*; D013997:Time Factors
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride